Tredje AP fonden Grows Holdings in McKesson Corporation $MCK

Tredje AP fonden raised its position in McKesson Corporation (NYSE:MCK) by 25.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 167,271 shares of the company’s stock after purchasing an additional 34,375 shares during the period. McKesson makes up approximately 1.0% of Tredje AP fonden’s investment portfolio, making the stock its 17th biggest position. Tredje AP fonden’s holdings in McKesson were worth $129,224,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of MCK. Norges Bank purchased a new position in McKesson in the second quarter valued at about $1,346,661,000. Alliancebernstein L.P. raised its position in shares of McKesson by 150.4% in the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock valued at $1,661,956,000 after purchasing an additional 1,362,386 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of McKesson by 56.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after buying an additional 446,060 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of McKesson by 45.6% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after buying an additional 261,296 shares in the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of McKesson by 68.0% during the second quarter. Acadian Asset Management LLC now owns 636,596 shares of the company’s stock worth $466,441,000 after buying an additional 257,670 shares in the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Stock Up 1.1%

MCK opened at $947.39 on Friday. The company’s 50-day moving average price is $853.65 and its 200 day moving average price is $795.74. McKesson Corporation has a fifty-two week low of $594.34 and a fifty-two week high of $971.93. The firm has a market cap of $116.05 billion, a price-to-earnings ratio of 27.25, a price-to-earnings-growth ratio of 1.51 and a beta of 0.40.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business’s revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Research analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Wells Fargo & Company increased their price objective on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research note on Thursday, February 5th. Wall Street Zen lowered shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Barclays lifted their price target on McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price objective on McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Finally, Evercore reaffirmed an “outperform” rating and set a $1,000.00 target price on shares of McKesson in a report on Thursday, November 6th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $943.50.

Insider Buying and Selling at McKesson

In other news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Leann B. Smith sold 190 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the transaction, the executive vice president owned 2,989 shares of the company’s stock, valued at $2,824,605. This represents a 5.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 794 shares of company stock worth $718,056. 0.08% of the stock is owned by insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.